OSMOTICA PHARM Current Ratio 2017-2021 | OSMT

OSMOTICA PHARM current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
OSMOTICA PHARM Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.25B $0.27B 0.94
2021-03-31 $0.16B $0.05B 3.32
2020-12-31 $0.17B $0.06B 3.10
2020-09-30 $0.18B $0.06B 3.21
2020-06-30 $0.19B $0.06B 3.17
2020-03-31 $0.19B $0.06B 3.26
2019-12-31 $0.17B $0.08B 2.27
2019-09-30 $0.17B $0.08B 2.13
2019-06-30 $0.17B $0.10B 1.78
2019-03-31 $0.16B $0.10B 1.70
2018-12-31 $0.17B $0.11B 1.51
2018-09-30 $0.15B $0.12B 1.29
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.00B 0.00
2016-12-31 $0.09B $0.12B 0.80
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.180B $0.178B
Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women's health. The company's product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29